Data collection
Data on patients’ demographics, underlying comorbidities, clinical
presentation, oxygen-support
requirements
and laboratory results were recorded. The time to SARS-CoV-2 RNA
clearance in respiratory specimens of patients with confirmed diagnosis
were also assessed. Virus clearance was defined as the time from
admission until the RT-PCR assay was negative on 2 occasions. To assess
Kaletra
and interferon alfa-2b safety profile, the occurrence of nausea,
diarrhea, rash and serial
levels
of white blood cell (WBC) count, neutrophil count, hemoglobin, platelet
count, aminotransferase, bilirubin, and creatinine kinase were evaluated
according to the National Cancer Institute Common Terminology Criteria
for Adverse Events, version 5.0..